Clinical Trials Logo

Clinical Trial Summary

In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. The study hypothesis is that G-CSF and EPO improve associative learning and/or motor skills.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00298597
Study type Interventional
Source University Hospital Muenster
Contact
Status Completed
Phase Phase 2
Start date March 2006
Completion date March 2009

See also
  Status Clinical Trial Phase
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Enrolling by invitation NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Not yet recruiting NCT03651349 - To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers Phase 1
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02590276 - Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) N/A
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A
Active, not recruiting NCT02567136 - Imaging Biomarkers in ALS
Completed NCT02059759 - Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 Phase 2
Recruiting NCT02405182 - MRI Biomarkers in ALS
Terminated NCT01999803 - A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS Phase 1
Completed NCT02492516 - Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS Phase 1
Completed NCT02238626 - Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT01935518 - A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02507713 - Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT01933321 - Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3
Completed NCT01823380 - Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype N/A
Terminated NCT01583088 - Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation Phase 3
Terminated NCT00982150 - Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT00860951 - P300 Brain Computer Interface Keyboard to Operate Assistive Technology Phase 1/Phase 2